ARVINAS Reports Positive Financial Results for Q2 of FY2023

August 24, 2023

☀️Earnings Overview

For the second quarter of the fiscal year 2023, ARVINAS ($NASDAQ:ARVN) reported total revenue of USD 54.5 million, a notable 74.1% increase from the same period in the prior year. Net income also showed an improvement, coming in at -66.6 million compared to the -70.0 million reported in Q2 of FY2022.

Stock Price

On Tuesday, ARVINAS announced its financial results for the second quarter of FY2023. The company reported positive financial results, which saw its stock price surge by 4.1% to close at $24.3. This was up from the previous closing price of $23.3, with the opening price set at $24.1. These positive financial results signify a strong outlook for the company as it continues to grow and develop its groundbreaking therapeutics that are revolutionizing the biopharmaceutical industry.

With the continued success and growth of ARVINAS, investors and shareholders have increased their confidence in the company, leading to a higher stock price. The company is looking to capitalize on its positive financial results and continue to grow its drug development pipelines, as well as increase its presence in the global market. With a strong focus on delivering innovative therapies to patients worldwide, ARVINAS is well-positioned to become a leading player in the biopharmaceutical industry in the years ahead. Live Quote…

About the Company

  • ARVINAS_Reports_Positive_Financial_Results_for_Q2_of_FY2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Arvinas. More…

    Total Revenues Net Income Net Margin
    162.9 -297.6 -182.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Arvinas. More…

    Operations Investing Financing
    -307.6 242.8 4.7
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Arvinas. More…

    Total Assets Total Liabilities Book Value Per Share
    1.08k 619.9 8.68
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Arvinas are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    51.4% -182.5%
    FCF Margin ROE ROA
    -192.4% -38.1% -17.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has conducted an analysis of ARVINAS‘s wellbeing, and we are proud to report that ARVINAS is a low risk investment in terms of both financial and business aspects. Our Risk Rating system has detected only 1 risk warning in the balance sheet, and we recommend that you register with us to find out more about it. At GoodWhale, we understand the importance of investing in the right companies, and we have the expertise to help you make the best decisions when it comes to investments. Our analysis of ARVINAS’s wellbeing means that you can trust us when it comes to making a safe and secure investment. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The biopharmaceutical industry is highly competitive, and Arvinas Inc is no exception. It faces tough competition from Syndax Pharmaceuticals Inc, Fate Therapeutics Inc, and Eterna Therapeutics Inc, all of whom are working to develop new treatments for a range of medical conditions. As these companies race to be the first to break new ground in drug development and treatment, Arvinas Inc must stay ahead of the game and maintain their competitive edge.

    – Syndax Pharmaceuticals Inc ($NASDAQ:SNDX)

    Syndax Pharmaceuticals Inc is a biopharmaceutical company that is focused on developing treatments for cancer and other serious diseases. As of 2023, the company has a market cap of 1.7 billion dollars. Its Return on Equity (ROE) is -1.94%, which indicates that the company is not currently generating sufficient profits to cover its investments and liabilities. The negative ROE may be a sign that the company is not making the most of its resources and investments, or may reflect a decline in its competitive position.

    – Fate Therapeutics Inc ($NASDAQ:FATE)

    Fate Therapeutics Inc is a biopharmaceutical company that develops engineered cellular immunotherapies for cancer and immune disorders. As of 2023, Fate Therapeutics Inc has a market cap of 1.08B. A company’s market cap is calculated by multiplying the current stock price by the total number of shares outstanding. Return on Equity (ROE) is a measure of how well a company is using its equity to generate profits. Fate Therapeutics Inc has a Return on Equity of -35.11%, which is lower than the industry average. This suggests that the company is not generating profits from its equity investments.

    – Eterna Therapeutics Inc ($NASDAQ:ERNA)

    Eterna Therapeutics Inc is a biopharmaceutical company that focuses on the development of therapies for the treatment of cancer and other diseases. As of 2023, the company has a market cap of 17.18M and a Return on Equity (ROE) of -147.05%. The market cap of 17.18M indicates that Eterna Therapeutics Inc is a small-cap company and its negative ROE suggests that the company’s net income is less than what stockholders have invested in it. This highlights the importance of investors being aware of the potential risks associated with investing in a small-cap company with a negative ROE.


    Investors in ARVINAS can draw optimism from the company’s latest financial results for Q2 of FY2023. Total revenue increased by an impressive 74.1% year-over-year, totaling USD 54.5 million. Furthermore, the reported net income for Q2 was -66.6 million, which is an improvement compared to the -70.0 million reported in the corresponding quarter of the previous year.

    Judging from the growth in revenue and net income, it is likely that ARVINAS’ stock price will remain stable or increase in the near future. Considering these results, investors should take a closer look at the company and consider investing in ARVINAS.

    Recent Posts

    Leave a Comment